Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (B...

por Saad, Fred, Chi, Kim N., Shore, Neal D., Graff, Julie N., Posadas, Edwin M., Lattouf, Jean-Baptiste, Espina, Byron M., Zhu, Eugene, Yu, Alex, Hazra, Anasuya, De Meulder, Marc, Mamidi, Rao N. V. S., Bradic, Branislav, Francis, Peter, Hayreh, Vinny, Rezazadeh Kalebasty, Arash
Publicado 2021

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair ge...

por Smith, Matthew R, Sandhu, Shahneen, George, Daniel J, Chi, Kim Nguyen, Saad, Fred, Thiery-Vuillemin, Antoine, Stàhl, Olaf, Olmos, David, Danila, Daniel C, Gafanov, Rustem, Castro, Elena, Moon, Helen, Joshua, Anthony M, Mason, Gary E, Espina, Byron M, Liu, Yan, Lopez-Gitlitz, Angela, Francis, Peter, Bevans, Katherine B, Fizazi, Karim
Publicado 2023